No supplier or customer ties in XCUR's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
How XCUR has moved on past release days vs its typical ±6.0% day, and how often it closed up. Computed from daily closes — not a forecast.